The Signature Program: Bringing the Protocol to the Patient

Early‐phase clinical development in oncology has evolved dramatically with the deciphering of the human genome in 2004. Genomic analysis and the tools identifying genetically disrupted pathways within a patient's tumor have been a driving force for personalized medicine and for the development...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, BP, Slosberg, E, Snodgrass, S, Lebedinsky, C, Berry, DA, Corless, CL, Stein, S, Salvado, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Development
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676287/
https://www.ncbi.nlm.nih.gov/pubmed/25810246
http://dx.doi.org/10.1002/cpt.126
Descripción
Sumario:Early‐phase clinical development in oncology has evolved dramatically with the deciphering of the human genome in 2004. Genomic analysis and the tools identifying genetically disrupted pathways within a patient's tumor have been a driving force for personalized medicine and for the development of highly targeted novel therapies. Tumors are often genetically heterogeneous, with multiple concurrent genetic abnormalities. On the other hand, tumors arising from different tissues may share identical molecular drivers.

Ejemplares similares